Mitsubishi Chemical Medience Corp announced that the FDA has granted 510(k) premarketing notification clearance to the PATHFAST® cTnI-II (cardiac Troponin I) diagnostic test, clearing the way for its sale in the US. The test is designed to be used with the PATHFAST analysis system, a unique, self-contained, benchtop chemi-luminescence immunoanalyzer that rapidly measures concentrations of emergency biomarkers from a single whole blood sample.
The PATHFAST cTnI-II test determines the quantity of cardiac troponin I, a protein that is integral to cardiac muscle contraction, which is elevated in the bloodstream after damage to the myocardium (the middle and thickest layer of the heart wall). Due to its absolute coronary specificity and high sensitivity, cardiac troponin I is considered the preferred biomarker for diagnosing cardiac muscle damage, particularly following a heart attack.
“We are pleased that the FDA has recognized the utility of the PATHFAST system for measuring levels of cardiac troponin I in whole blood, and are confident the test will be widely accepted in the U.S. market, in accordance with international guidelines,” commented Toshihiko Yoshitomi, president and CEO of Mitsubishi Chemical Medience. “Today’s news is also an important step in supporting our ongoing negotiations to secure a strategic distribution partnership to launch the PATHFAST product line in the US by early 2012.”
The 510(k) clearance of the PATHFAST cTnI-II test completes the cardiovascular product line of the PATHFAST analysis system, which also includes tests to determine quantities of N-terminal pro brain natriuretic peptide (NT-proBNP), D-Dimer, myoglobin, creatinine kinase (CK)-MB, and high-sensitivity C-reactive protein (hsCRP). With its whole blood use capability, the PATHFAST system eliminates the need for centrifugation of the specimen preparation, and can be used with either plasma or serum. The system has a 17-minute turnaround time, a feature that can significantly reduce testing time, which can be a key consideration in a clinical laboratory or point-of-care (POC) setting.
Mitsubishi Chemical Medience and Mitsubishi Chemical Europe have sold more than 1,000 units of the PATHFAST system in Asia, Europe, and Latin America. The PATHFAST cTnI-II test is considered “guideline acceptable” by virtue of its minimal imprecision, as measured by a coefficient of variance (CV) of ≤10% at the 99th percentile. By generating precise, accurate, and rapid results, the PATHFAST cTnI-II test is expected to enhance patient safety by streamlining coordination between emergency POC and central laboratories. It may be particularly useful in the emergency room (ER) setting, as well as in satellite laboratories, physician laboratories, and central laboratories.
Source: Mitsubishi Chemical Medience Corp